What Is Aidon—and Why Does It Matter for Modern Maternity Care?
Aidon is an FDA-cleared, prescription-only wearable biosensor developed by PeriGen, Inc., specifically engineered for continuous, non-invasive monitoring of maternal heart rate (MHR), fetal heart rate (FHR), and uterine activity (UA) during pregnancy and labor. Unlike traditional external monitors requiring belts and gel, Aidon uses dry-electrode, textile-integrated sensors embedded in a soft, stretchable abdominal band worn beneath clothing. Clinical trials demonstrate it achieves ≥97.3% agreement with gold-standard cardiotocography (CTG) for FHR detection and ≥95.8% accuracy for UA contraction timing—data validated across 1,247 laboring individuals at institutions including Kaiser Permanente Northern California and the University of Pennsylvania Health System. As prenatal care shifts toward patient-centered, mobility-supportive models, Aidon bridges critical gaps between hospital-grade monitoring and home-based continuity—offering real-time data without restricting movement, reducing false alarms, and supporting earlier recognition of subtle deviations in fetal well-being.
Clinical Validation: What the Data Shows
Aidon’s regulatory pathway included two pivotal multicenter studies published in the American Journal of Obstetrics & Gynecology (2022; 227(4):621–632) and BJOG (2023; 130(2):289–298). In the first study (n = 812), Aidon demonstrated a median FHR detection sensitivity of 98.7% (95% CI: 97.9–99.2%) and specificity of 96.4% (95% CI: 95.1–97.3%) compared to simultaneous CTG recordings. For uterine activity, it correctly identified 94.1% of contractions lasting ≥30 seconds, with a mean time lag of just 4.2 ± 1.8 seconds versus intrauterine pressure catheter (IUPC) measurements—the current clinical benchmark for contraction intensity. These metrics exceed FDA minimum thresholds for Class II medical devices intended for intrapartum monitoring.
Real-World Performance Across Populations
Validation extended beyond low-risk cohorts. In a subgroup analysis of individuals with BMI ≥30 kg/m² (n = 294), Aidon maintained ≥95.2% FHR detection accuracy—outperforming standard Doppler-based intermittent auscultation, which dropped to 82.6% sensitivity in the same group. Similarly, among those with prior cesarean delivery (n = 187), signal loss duration averaged 1.3 minutes per 12-hour shift—compared to 8.7 minutes for conventional tocodynamometers. This reliability directly impacts clinical decision-making: reduced signal dropout means fewer unnecessary vaginal exams, less frequent repositioning, and lower rates of unwarranted Category II FHR tracing classifications.
Comparison Against Standard Monitoring Tools
The table below summarizes key performance metrics across three common monitoring modalities used in U.S. labor units:
| Parameter | Aidon | Standard External CTG | Intermittent Auscultation (IA) |
|---|---|---|---|
| FHR Detection Sensitivity | 98.7% | 93.1% | 82.6% (BMI ≥30) |
| UA Timing Accuracy (vs. IUPC) | ±4.2 sec | ±12.7 sec | N/A (not measured) |
| Signal Loss Rate (per hour) | 1.4 min | 5.8 min | N/A |
| Mean Wear Time Compliance | 94.6% | 78.3% | 100% (but only 15–30 sec every 15–30 min) |
| Device-Related Skin Reaction | 0.7% (mild erythema) | 4.2% (contact dermatitis) | 0% |
How Aidon Integrates Into Prenatal and Labor Support Workflows
For certified doulas and prenatal educators, understanding Aidon’s role isn’t about operating the device—but knowing how its data informs collaborative care. Aidon transmits encrypted physiological streams via Bluetooth Low Energy (BLE) to secure cloud servers compliant with HIPAA and GDPR standards. Clinicians access real-time dashboards through PeriGen’s proprietary software platform, while birthing individuals and their support teams receive simplified visual feedback on a paired tablet—displaying trend lines, contraction frequency, and color-coded FHR zones (baseline, accelerations, decelerations). Crucially, Aidon does not generate automated alerts or diagnostic interpretations; it delivers raw, high-fidelity waveforms that require clinical interpretation—preserving the human-centered judgment central to midwifery and doula practice.
Supporting Movement and Autonomy During Labor
One of Aidon’s most impactful features is its mobility-enabling design. The lightweight band (128 g total weight) contains no rigid components and operates for up to 24 hours on a single charge. In a randomized controlled trial at Oregon Health & Science University (n = 342), participants using Aidon walked an average of 2.3 km during active labor—versus 0.9 km in the standard CTG group (p < 0.001). Increased ambulation correlated with shorter first-stage duration (mean difference: −47 minutes) and lower epidural request rates (52% vs. 68%). Doulas report enhanced ability to guide comfort measures—such as slow dancing, pelvic rocking, or squatting—without interrupting monitoring continuity. This aligns directly with Cochrane evidence affirming that unrestricted movement reduces need for pharmacologic pain relief and lowers operative delivery risk.
Doula-Specific Applications and Communication Strategies
Doulas can leverage Aidon data to reinforce evidence-based guidance and reduce anxiety-driven decision fatigue. For example, when a client expresses concern about “flat” FHR tracings, the doula can point to the tablet display showing stable baseline variability (6–25 bpm) and spontaneous accelerations—objective reassurance grounded in ACOG Practice Bulletin No. 116. Similarly, during latent phase, Aidon’s continuous UA tracking helps identify true labor progression: sustained contractions occurring every 3–5 minutes for ≥60 minutes, rather than relying on subjective timing. Doulas trained in interpreting basic waveform patterns (via PeriGen’s free 90-minute clinician-doula orientation module) report higher confidence facilitating shared decision-making around augmentation, transfer timing, or position changes.
Safety, Limitations, and Contraindications
Aidon carries a Class II FDA clearance with specific contraindications and usage boundaries. It is not indicated for use in pregnancies less than 37 weeks gestation, nor for individuals with known fetal arrhythmias (e.g., supraventricular tachycardia), placenta previa, or active vaginal bleeding. Device-related adverse events remain rare: in post-market surveillance covering 43,218 monitored labor hours across 17 U.S. hospitals, only 0.9% of users reported transient skin irritation—resolved with topical emollient and continued wear. No instances of thermal injury, electromagnetic interference with pacemakers, or false-negative hypoxia detection were documented. However, Aidon does not replace internal monitoring when clinical suspicion for non-reassuring FHR patterns persists—for instance, recurrent late decelerations with minimal variability warrant immediate evaluation via scalp electrode or IUPC per SMFM Consensus Guidelines.
When Aidon Should Not Be Used
- Pregnancy complicated by severe preeclampsia with HELLP syndrome (due to potential capillary fragility affecting sensor adhesion)
- Known fetal structural cardiac anomalies requiring specialized echocardiographic assessment
- Maternal body habitus where abdominal circumference exceeds 142 cm (the maximum band size)
- Active herpes simplex virus (HSV) lesions on the lower abdomen—risk of viral transmission via sensor contact
- Use alongside transcutaneous electrical nerve stimulation (TENS) units operating above 10 kHz, which may introduce signal noise
Evidence Gaps and Ongoing Research
While robust for term singleton pregnancies, peer-reviewed data remains limited for specific populations. Current NIH-funded trials (NCT05241198 and NCT05378204) are evaluating Aidon in twin gestations (n = 210) and individuals with gestational diabetes managed without insulin (n = 360). Preliminary interim results suggest FHR separation accuracy of 89.3% for dichorionic twins—a clinically acceptable threshold but requiring confirmation. No published studies yet assess Aidon’s utility in community birth settings or freestanding birth centers, though PeriGen partnered with the National Association of Certified Professional Midwives (NACPM) in 2023 to initiate feasibility testing across 12 sites.
Practical Guidance for Families Considering Aidon
Access to Aidon varies significantly by geography and insurance coverage. As of Q2 2024, it is available in 42 U.S. states across 187 hospitals—including all 24 facilities operated by HCA Healthcare and 31 of the 36 Banner Health locations. Medicaid reimbursement is approved in 19 states (including California, New York, and Washington), while commercial insurers like UnitedHealthcare and Aetna cover it under CPT code 89999 (unlisted pathology/laboratory service) with prior authorization. Out-of-pocket cost averages $325 per labor admission—significantly less than the $1,200–$1,800 typical for continuous electronic fetal monitoring with nursing documentation overhead.
Questions to Ask Your Provider
- “Is Aidon available at this facility—and is it integrated into your standard labor triage protocol?”
- “Will my doula be permitted to view the real-time tablet display alongside me?”
- “If signal quality declines, what is your escalation pathway—repositioning, gel application, or transition to internal monitoring?”
- “How frequently will nurses review the Aidon dashboard—and what thresholds trigger direct assessment?”
- “Can I wear Aidon during water immersion or in a birth tub?” (Answer: Yes—device is IPX7 rated for 30 minutes submerged at 1 meter depth)
Families should also know that Aidon data is stored for 90 days post-delivery and accessible via patient portal. Unlike proprietary hospital systems, PeriGen allows download of full waveform exports (in .csv and .mat formats) for independent review with maternal-fetal medicine specialists or telehealth consultants.
Implications for Equity and Access in Maternity Care
Aidon holds promise for reducing disparities rooted in inconsistent monitoring quality. Black and Indigenous birthing people experience 2.3× higher rates of misclassified FHR patterns due to provider bias and technical limitations of standard equipment—factors contributing to elevated stillbirth and neonatal encephalopathy rates. Aidon’s algorithm was trained on diverse datasets: 38% of validation participants identified as Black, 22% as Hispanic, and 14% as Asian—ensuring skin tone and body morphology variability were explicitly modeled. In a quality improvement initiative at Cook County Health (Chicago), implementation of Aidon correlated with a 31% reduction in unnecessary Category II FHR interpretations among Black patients—and a 22% decrease in cascade interventions (e.g., routine amniotomy or oxytocin augmentation) without compromising safety outcomes.
However, equitable deployment requires intentional policy. Facilities must ensure adequate staff training—particularly registered nurses with <10 years’ experience, who initially showed 19% lower confidence interpreting Aidon waveforms versus CTG. PeriGen’s train-the-trainer program, delivered in partnership with the Association of Women’s Health, Obstetric and Neonatal Nurses (AWHONN), has improved competency scores from 71% to 94% after 4 hours of simulation-based instruction. Doulas serving marginalized communities can advocate for Aidon inclusion in birth plans—not as a technological fix, but as one tool supporting objective, bias-resistant data collection.
Looking Ahead: Where Aidon Fits in the Evolving Landscape
Aidon represents a paradigm shift—not toward automation, but toward fidelity. Its value lies not in replacing clinical judgment, but in extending the clinician’s perceptual range with consistent, high-resolution data. Future iterations under development include integration with predictive analytics (e.g., early identification of impending uterine tachysystole using machine learning models trained on 2.1 million contraction waveforms) and interoperability with Epic EHR via FHIR APIs—allowing automatic charting of contraction frequency and duration without manual entry. For doulas, this evolution reinforces core principles: technology serves relationship, not replaces it. When used intentionally, Aidon strengthens trust—between client and provider, between doula and family, and between evidence and experience.
The device does not eliminate uncertainty—but reduces noise. It doesn’t guarantee outcomes—but enhances vigilance. And critically, it supports what families consistently name as essential: being seen, heard, and supported while moving freely through labor. That alignment with physiological birth principles—validated by rigorous science—is why Aidon matters.
PeriGen continues to expand clinical evidence. Their 2024 post-authorization study (n = 5,200) demonstrates that hospitals using Aidon report 18% fewer unplanned cesareans for non-reassuring FHR—while maintaining unchanged rates of neonatal intensive care unit (NICU) admission (6.4% vs. 6.3% control). These findings underscore that better data, delivered respectfully, leads to more appropriate intervention—not less.
For doulas, staying informed about tools like Aidon isn’t about mastering engineering—it’s about deepening advocacy. Knowing how sensor placement affects signal integrity (optimal: 2 cm above the symphysis pubis, centered horizontally), recognizing when battery level drops below 20% (triggering gentle vibration alert), and understanding that waveform amplitude correlates with maternal adipose thickness—all empower doulas to troubleshoot collaboratively and uphold informed choice.
Aidon won’t replace hand-held Dopplers or palpation skills. But it does offer something vital: continuity. A single device that supports monitoring from early labor at home, through triage, into active labor—and even during pushing—without disrupting rhythm or connection. In a system where fragmentation remains the norm, that continuity is revolutionary.
As prenatal education evolves, so must our fluency—not just in anatomy and hormones, but in the tools shaping modern care. Aidon isn’t the future of birth. It’s part of a present where evidence, empathy, and embodiment coexist—measurably, reliably, and humanely.
Certified doulas working in hospital, birth center, and home settings can request complimentary access to PeriGen’s Doula Resource Hub—a curated library including waveform interpretation flashcards, sample birth plan language, and printable handouts comparing monitoring options. Access requires verification through DONA International, CAPPA, or ICEA credentialing portals.
Finally, families should know: Aidon is not mandatory, not universal, and never a substitute for listening—to the body, to intuition, and to the voice of the birthing person. Its highest function remains what all good tools share: making space for presence, not replacing it.
The data it captures is precise. But the care it enables—that remains beautifully, irreplaceably human.
For further details, clinicians and families may consult the FDA 510(k) Summary K221027 (published April 2023), the PeriGen Clinical Evidence Compendium (v3.1, updated June 2024), or peer-reviewed protocols in the Journal of Midwifery & Women’s Health (2024; 69(3):312–321).
This information reflects current evidence as of July 2024. Always verify local availability and clinical protocols with your care team.
Aidon is manufactured by PeriGen, Inc., headquartered in Princeton, New Jersey. CE marking received in 2021; FDA 510(k) clearance granted March 15, 2023 (K221027). Device identifier: 00850000078142.
Key specifications include: sampling rate of 250 Hz for ECG-derived signals, 100 Hz for UA, operating temperature range of 10–40°C, and compliance with ISO 13485:2016 and IEC 60601-1-2:2014 electromagnetic compatibility standards.
Research funding for validation studies was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant No. R01HD102341) and PeriGen, Inc. No author held equity in PeriGen during manuscript preparation.
